ISOLATION AND CHARACTERIZATION OF MONOCLONAL ANTIBODIES SPECIFIC FOR THE EXTRACELLULAR DOMAIN OF PROSTATE SPECIFIC MEMBRANE ANTIGEN

Abstract

No AccessJournal of UrologyFestschrift in Honor of 85th Birthday of Dr. William Wallace Scott, Sr1 Dec 1998ISOLATION AND CHARACTERIZATION OF MONOCLONAL ANTIBODIES SPECIFIC FOR THE EXTRACELLULAR DOMAIN OF PROSTATE SPECIFIC MEMBRANE ANTIGEN GERALD P. MURPHY, THOMAS G. GREENE, WILLIAM T. TINO, ALTON L. BOYNTON, and ERIC H. HOLMES GERALD P. MURPHYGERALD P. MURPHY , THOMAS G. GREENETHOMAS G. GREENE , WILLIAM T. TINOWILLIAM T. TINO , ALTON L. BOYNTONALTON L. BOYNTON , and ERIC H. HOLMESERIC H. HOLMES View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)62198-0AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Monoclonal antibodies specific for protein epitopes of prostate specific membrane antigen (PSMA) expressed on the external surface of prostatic epithelial cells were prepared to provide material for use in the diagnosis or treatment of prostatic cancer. Materials and Methods: Mice were immunized with LNCaP cell membranes followed by purified PSMA before fusion. Hybridomas were screened by reactivity with purified PSMA. Resulting antibodies were characterized by enzyme-linked immunosorbent assay, Western blot and fluorescence-activated cell sorter analyses. Results: Monoclonal antibody producing hybridomas designated 3E11, EC2, 4E10-1.14, 3C9 and 1G3 were obtained which displayed specificities for differing regions of the extracellular domain of the PSMA protein. These antibodies reacted strongly with PSMA from multiple sources and specifically stained unfixed PSMA expressing cells by flow cytometric analysis. Conclusions: The antibodies obtained displayed strong reactivity and specificity for extracellular epitopes of PSMA. These antibodies will have value in future diagnostic and therapeutic applications focusing on PSMA as a target antigen. References 1 : Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res.1993; 53: 227. Google Scholar 2 : Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res1987; 7: 927. Google Scholar 3 : Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int. J. Cancer1995; 62: 552. Google Scholar 4 : Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5. Cancer Res.1990; 50: 6423. Google Scholar 5 : In vitro and in vivo reactivity of anti-prostate monoclonal antibody immunoconjugate 7E11.C5.3-GYK-DTPA. Antibody Immunoconjugates Radiopharmaceut1990; 3: 54. Google Scholar 6 : Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res.1997; 3: 81. Google Scholar 7 : Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: study of 184 cases. Cancer1998; 82: 2256. Google Scholar 8 : Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate-specific membrane antigen. Urol. Oncol.1995; 1: 29. Google Scholar 9 : Modulation of prostate specific membrane antigen (PSM) expression in vitro by cytokines and growth factors. J. Urol.1995; 153: 382A. abstract 614. Google Scholar 10 : Upregulation of prostate-specific antigen after androgen deprivation therapy. Urology1996; 48: 326. Google Scholar 11 : Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res.1997; 57: 2321. Google Scholar 12 : Localization and physical mapping of the prostate-specific membrane antigen (PSM) gene to human chromosome 11. Genomics1995; 30: 105. Google Scholar 13 : Prostate-specific membrane antigen: evidence for existence of a second related human gene. Brit. J. Cancer1995; 72: 583. Google Scholar 14 : Immunoscintigraphy of prostatic cancer: preliminary results with111 In-labeled monoclonal antibody 7E11-C5.3 (CYT-356). Prostate1991; 18: 229. Google Scholar 15 : Monoclonal antibodies and radioimmunoconjugates in the diagnosis and treatment of prostate cancer. Sem. Urol.1992; 10: 45. Medline, Google Scholar 16 : Radioimmunoscintigraphy of pelvic lymph nodes with111 indium-labeled monoclonal antibody CYT-356. J. Urol.1994; 152: 1952. Link, Google Scholar 17 : Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen: positron emission tomography and biopsy correlation. Clin. Nucl. Med.1996; 21: 703. Google Scholar 18 : Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients. Anticancer Res.1995; 15: 1473. Google Scholar 19 : Comparison of serum PSMA, PSA levels with results of Cytogen-356 ProstaScint scanning in prostatic cancer patients. Prostate1997; 33: 281. Google Scholar 20 : Measurement of prostate-specific membrane antigen in the serum with a new antibody. Prostate1996; 28: 266. Google Scholar 21 : Immunoglobulin-producing hybrid cell lines. In: Selected Methods in Cellular Immunology. Edited by . New York: Freeman1980: 351. Google Scholar 22 : Identification of PSM protein in cytoplasm of the prostate carcinoma cell line, LNCaP. Proc. Amer. Assn. Cancer Res.1998; 39: 554. Google Scholar 23 : Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res.1995; 55: 1441. Google Scholar 24 : Analysis of glycosylation of prostate-specific membrane antigen derived from LNCaP cells, prostatic carcinoma tumors, and serum from prostate cancer patients. Prostate1996; 7: 25. Google Scholar 25 : Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate1996; 29: 371. Crossref, Medline, Google Scholar 26 : Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate1997; 32: 272. Google Scholar 27 : Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res.1997; 57: 3629. Medline, Google Scholar From the Northwest Hospital, Pacific Northwest Cancer Foundation and Northwest Biotherapeutics, Seattle, Washington(MURPHY) Supported by research funds provided by Hybritech, Inc. and Phi Beta Psi Sorority.© 1998 by American Urological Association, Inc.FiguresReferencesRelatedDetails Volume 160Issue 6 Part 2December 1998Page: 2396-2401 Advertisement Copyright & Permissions© 1998 by American Urological Association, Inc.Keywordsantibodiesprostatic neoplasmsprostate-specific antigenmonoclonalcell membraneMetricsAuthor Information GERALD P. MURPHY More articles by this author THOMAS G. GREENE More articles by this author WILLIAM T. TINO More articles by this author ALTON L. BOYNTON More articles by this author ERIC H. HOLMES More articles by this author Expand All Advertisement PDF downloadLoading ...